European Archives of Oto-Rhino-Laryngology

, Volume 269, Issue 3, pp 1027–1033 | Cite as

Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma

  • He Xiayun
  • Dan Ou
  • Hongmei Ying
  • Guopei Zhu
  • Chaosu HuEmail author
  • Taifu Liu
Head and Neck


The purpose of this study was to evaluate the efficacy and toxicity of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiation therapy (IMRT) for locoregionally advanced nasopharyngeal carcinoma (NPC). A total of 54 patients (stage IIB: 6, stage III: 24, stage IVA–B: 24) with locoregionally advanced NPC were treated with cisplatin 25 mg/m2 intravenously on days 1–3, and gemcitabine 1,000 mg/m2 of 30-min intravenous infusion on days 1 and 8, every 3 weeks for two cycles as neoadjuvant chemotherapy. Two cycles of the same regimen were administered as adjuvant chemotherapy 28 days after the end of radiotherapy. The prescription doses were 66–70.4 Gy to the gross tumor volume (GTV), 66 Gy to positive neck nodes, 60 Gy to the high-risk clinical target volume and 54 Gy to the low-risk clinical target volume. The overall response rate to neoadjuvant chemotherapy was 88.6%. Toxicity was mainly grade 1/2 myelosuppression. All patients completed IMRT. The median follow-up duration was 30 months (range, 12–60 months). The 3-year locoregional control, metastasis-free rate and overall survival were 94.9%, 86.2% and 87.7%, respectively. Severe late toxicities included grade 3 trismus in one patient, grade 3 hearing impairment in one patient and cranial nerve XII palsy in one patient. No grade 4 late toxicities were observed. A combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced NPC is well-tolerated, convenient, effective and warrants further studies.


Cisplatin Gemcitabine Intensity-modulated radiation therapy Nasopharyngeal carcinoma 


  1. 1.
    Chen CY, Han F, Zhao C et al (2009) Treatment results and late complication of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. Br J Radial 82:452–458CrossRefGoogle Scholar
  2. 2.
    Lee AW, Tung SY, Chua DT et al (2010) Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 102:1188–1198PubMedCrossRefGoogle Scholar
  3. 3.
    Yi JL, Gao L, Huang XD et al (2006) Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys 65(1):161–168PubMedCrossRefGoogle Scholar
  4. 4.
    Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62:672–679PubMedCrossRefGoogle Scholar
  5. 5.
    Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116PubMedCrossRefGoogle Scholar
  6. 6.
    Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317PubMedGoogle Scholar
  7. 7.
    Lee AW, Lau WH, Tung SY et al (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966–6975PubMedCrossRefGoogle Scholar
  8. 8.
    Lin JC, Jan JS, Hsu CY et al (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21:631–637PubMedCrossRefGoogle Scholar
  9. 9.
    Chan AT, Teo PM, Ngan RK et al (2002) Concurrent chemotherapy–radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma; progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20:2038–2044PubMedCrossRefGoogle Scholar
  10. 10.
    Tham IW, Hee SW, Yeo RM et al (2009) Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre Singapore experience. Int J Radiat Oncol Biol Phys 75:1481–1486PubMedCrossRefGoogle Scholar
  11. 11.
    Lin S, Lu JJ, Han L et al (2010) Sequential chemotherapy and intensity modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer 10:39PubMedCrossRefGoogle Scholar
  12. 12.
    Lee N, Harris J, Garden AS et al (2009) Intensity-modulated radiotherapy therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol 27:3684–3690PubMedCrossRefGoogle Scholar
  13. 13.
    Han L, Lin SJ, Pan JJ et al (2010) Prognostic factor of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 29:153–158Google Scholar
  14. 14.
    Wang J, Li J, Hong X et al (2008) Retrospective case series of gemcitabine and cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol 44:464–470PubMedCrossRefGoogle Scholar
  15. 15.
    Ngan RK, Yiu HH, Lau WH et al (2002) Combination gemcitabine plus cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 13:1252–1258PubMedCrossRefGoogle Scholar
  16. 16.
    Chua DT, Sham JS, Au GK (2005) Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol 28:464–471PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang Y, Wei YQ, Luo F et al (2005) Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Invest 23:123–128PubMedGoogle Scholar
  18. 18.
    Yau TK, Lee AW, Wong DH et al (2006) Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck 28:880–887PubMedCrossRefGoogle Scholar
  19. 19.
    Yau TK, Lee AW, Wong DH et al (2006) Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int J Radiat Biol Phys 66(4):1004–1010CrossRefGoogle Scholar
  20. 20.
    Fan Y, Lin NM, Ma SL et al (2010) Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer. Acta Pharmacol Sin 31:746–752PubMedCrossRefGoogle Scholar
  21. 21.
    Squadroni M, Fazio N (2010) Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci 14:386–394PubMedGoogle Scholar
  22. 22.
    Yardley DA, Peacock NW, Dickson NR (2010) A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. Clin Breast Cancer 10:217–223PubMedCrossRefGoogle Scholar
  23. 23.
    Ibrahim SM, Abd El-Hafeez ZM, Mohamed EM et al (2007) Transurethral resection of bladder tumor (TUR-BT) then concomitant radiation and cisplatin followed by adjuvant gemcitabine and cisplatin in muscle invasive transitional cell carcinoma (TCC) of the urinary bladder. J Egypt Natl Cancer Inst 19:77–86Google Scholar
  24. 24.
    Verma AK, Arya AK, Kumar M et al (2009) Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: result from an observational study. J Gynecol Oncol 20:221–226PubMedCrossRefGoogle Scholar
  25. 25.
    Wang JL, Hong XN, Tang WY et al (2005) Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer. Zhonghua Zhong Liu Za Zhi 27:567–569PubMedGoogle Scholar
  26. 26.
    Specenier PM, Weyler J, Van Laer C et al (2009) A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 9:273PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • He Xiayun
    • 1
    • 2
  • Dan Ou
    • 1
    • 2
  • Hongmei Ying
    • 1
    • 2
  • Guopei Zhu
    • 1
    • 2
  • Chaosu Hu
    • 1
    • 2
    Email author
  • Taifu Liu
    • 1
    • 2
  1. 1.Department of Radiation OncologyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations